Flublok

What is Flublok?[edit | edit source]

Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza A subtype viruses and influenza type B viruses contained in the vaccine.

Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza A subtype viruses and influenza B viruses contained in the vaccine.

Flublok Quadrivalent contains recombinant HA proteins of the four strains of influenza virus specified by health authorities for inclusion in the annual seasonal vaccine. These proteins function as antigens which induce a humoral immune response, measured by hemagglutination inhibition (HI) antibody.

This medicine cannot be used in patients with:

with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine.

Data evaluating the concomitant administration of Flublok Quadrivalent with other vaccines are not available.

Recommended Dosage:

Administration

Invert the prefilled syringe containing Flublok Quadrivalent gently prior to affixing the appropriate size needle for intramuscular administration.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.
The preferred site for injection is the deltoid muscle. Flublok Quadrivalent should not be mixed in the same syringe with any other vaccine.

This medicine is available in fallowing doasage form:

As a sterile solution for injection supplied in 0.5 mL single dose prefilled syringes.

This medicine is available in fallowing brand namesː

The most common side effects of this medicine include:

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
The 1976 swine influenza vaccine was associated with an increased frequency of Guillain-Barré Syndrome (GBS). If Guillain Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give Flublok Quadrivalent should be based on careful consideration of potential benefits and risks.
If Flublok Quadrivalent is administered to immunocompromised individuals, including persons receiving immunosuppressive therapy, the immune response may be diminished.
Vaccination with Flublok Quadrivalent may not protect all vaccine recipients.

In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Overdose related information is also available online at poisonhelp.org/help.
In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Pregnancy outcomes in women exposed to Flublok Quadrivalent during pregnancy are being monitored. Contact: Sanofi Pasteur Inc. by calling 1-800-822-2463.

Safety and effectiveness of Flublok Quadrivalent have not been established in children 3 years to less than 18 years of age.

Active Ingredient:

Inactive ingredients:

Manufactured by Protein Sciences Corporation (Meriden, CT).

Distributed by Sanofi Pasteur Inc.

Flublok Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.